Monthly Archives: September 2020
On September 25th, the Indian Council for Medical Research (ICMR) announced that it has validated and approved Vstrip® COVID-19 Antigen Rapid Test as satisfactory and meets the minimum acceptance criteria of sensitivity and specificity of rapid antigen test kits.
ALK gene fusion occurs in approximately 3%-5% of NSCLC patients. Currently, there are 5 FDA approved tyrosine kinase inhibitors (TKI): crizotinib (first generation), ceritinib, alectinib, brigatinib (second generation), lorlatinib (third generation).
Currently, olaparib has been approved by the US. FDA for treating HER2-negative breast cancer patients who had a germline BRCA mutation. In phase I/II MEDIOLA study, the activity of olaparib in combined with durvalumab in various solid tumors were examined.
Gene fusion is one of the tumourigenic mechanisms as a drug target. For example, ALK, ROS1, RET, and NTRK1/2/3 gene fusions are identified as the druggable mutation across solid tumors. NRG1 gene fusion is an other druggable fusion, which activates ErbB signal pathways and promotes tumor growth. Drugs for blocking ErbB signal pathways are considered as treatment options for cancers with NRG1 gene fusion.
- 1
- 2